Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab PK and Safety Study in Healthy Participants
NCT04495478Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2020
- Primary completion
- May 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ramucirumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, non-small cell lung cancer (NSCLC) and 2 more (7 arms), sponsored by Eli Lilly and Company. Primary endpoints: Serious Adverse Events at Day 90, Injection Site Reactions at Day 90 and 2 more. Started Jul 2020; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04495478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495478.